

Corresponding author(s):	Joseph Loscalzo
Last updated by author(s):	May 15, 2019

## **Reporting Summary**

X Life sciences

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Statistics				
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed				
The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement				
statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
A description of all covariates tested				
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.				
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
$\square$ Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated				
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software and code				
Policy information about <u>availability of computer code</u>				
Data collection Whole-exome sequencing data and RNA-seq data were collected from TCGA database. All drug-target networks and human interactome used in this study are provided in the Supplemental data and Supplemental Materials.				
Data analysis  All specific softwares and codes used in this study are provided in the Methods section. The code for GPSnet analysis is available at https://github.com/ChengF-Lab/GPSnet.				
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.				
Data				
Policy information about <u>availability of data</u> All manuscripts must include a <u>data availability statement</u> . This statement should provide the following information, where applicable:  - Accession codes, unique identifiers, or web links for publicly available datasets  - A list of figures that have associated raw data  - A description of any restrictions on data availability				
Provide your data availability statement here.				
Field-specific reporting				

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Ecological, evolutionary & environmental sciences

Behavioural & social sciences

All studies must dis	sclose on the	ese points even when the disclosure is negative.	
Sample size	NA		
Data exclusions	NA		
Replication	NA		
Randomization	NA		
Blinding	NA		
We require informati system or method lis	ion from autho ted is relevant	specific materials, systems and methods  ors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.  Il systems  Methods	
Materials & experimental systems  n/a   Involved in the study		n/a Involved in the study	
Antibodies		ChIP-seq	
Eukaryotic		Flow cytometry	
Palaeontol Animals ar	logy nd other organi	MRI-based neuroimaging	
	search participa		
Clinical dat	ta		
Antibodies			
Antibodies used		Antibodies used in this study are provided in the Supplementary Table 1.	
Validation		NA	
Eukaryotic c	ell lines		
Policy information		n <u>es</u>	
Cell line source(s	5)	NSCLC cell lines A549, H522, H596, H1975, HCC827, and PC9 were obtained from the American Type Culture Collection (Manassas, VA) and cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium supplemented with 10% fetal bovine source (FBS, Gibcs), and popicillin strontomycin, Lung pormal cell lines MPC5 and W/22 were obtained from the Shanghai Cell	

All six cancer cell lines were authenticated by the American Type Culture Collection (Manassas, VA).

Bank of the Chinese Academy of Sciences.

NO

NO

Authentication

(See <u>ICLAC</u> register)

Mycoplasma contamination

Commonly misidentified lines